Detalhe da pesquisa
1.
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Proc Natl Acad Sci U S A
; 119(32): e2119514119, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35914158
2.
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Cancer
; 130(11): 1991-2002, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38404184
3.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10391): 1853-1865, 2023 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075781
4.
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Hepatology
; 77(3): 729-744, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302667
5.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future Oncol
; 19(38): 2505-2516, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671641
6.
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Gut
; 71(1): 185-193, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33431577
7.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(8): 995-1008, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35798016
8.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914889
9.
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Oncologist
; 27(12): e938-e948, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190331
10.
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Invest New Drugs
; 40(2): 314-321, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735674
11.
Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs.
Clin Exp Rheumatol
; 40(5): 913-920, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34369368
12.
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.
Postgrad Med J
; 98(1163): 666-669, 2022 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062975
13.
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Cancer
; 127(6): 865-874, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231873
14.
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Gastroenterology
; 159(2): 609-623, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32275969
15.
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Breast Cancer Res Treat
; 189(3): 665-676, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34553296
16.
The Effects of COVID-19 on Cancer Care Provision: A Systematic Review.
Cancer Control
; 28: 1073274821997425, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631953
17.
Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
J Gastroenterol Hepatol
; 36(9): 2601-2609, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33656759
18.
Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Endocr Pract
; 27(9): 886-893, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581327
19.
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol
; 73(6): 1460-1469, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32710922
20.
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
J Gastroenterol Hepatol
; 35(8): 1307-1316, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900959